Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia

Pharmacotherapy

Volumn 26, Issue 4, 2006, Pages 461-468

  Dang, Cathyyen H ^a   Durkalski, Valerie L ^b   Nappi, Jean M ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Anticoagulation; Argatroban; Bivalirudin; Direct thrombin inhibitors; Heparin induced thrombocytopenia; HIT; Lepirudin

Indexed keywords

ARGATROBAN; HEPARIN; HIRULOG; LEPIRUDIN; THROMBIN INHIBITOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEALTH CARE COST; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIMB AMPUTATION; MALE; MORTALITY; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDY; STROKE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBIN; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 33645686878     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.4.461     Document Type: Article

References (14)

1. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8.
2. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163:2518-24.
3. Hourigan LA, Waters DI, Keck SA, Dec GW. Heparin induced thrombocytopenia: a common complication in cardiac transplant recipients. J Heart Lung Transplant 2002;21:1283-9.
4. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
5. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005;127:35S-45.
6. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:311S-37.
7. Call JT, Deliargyris EN, Sane DC. Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia. Semin Thromb Hemost 2004;30:297-304.
8. Reid T III, Alving BM. Hirolog therapy for heparin-associated thrombocytopenia and deep vein thrombosis. Am J Hematol 1994;45:352-3.
9. Chamberlin JR, Lewis B, Leya F, et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using hirolog. Can J Cardiol 1995;11:511-14.
10. GlaxoSmithKline. Argatroban package insert. Bellaire, TX; 2005.
11. Berlex. Refludan (lepirudin) package insert. Montville, NJ; 2004.
12. Verme-Gibboney CN, Bursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:970-5.
13. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
14. Murray L, ed. Red book: pharmacy's fundamental reference. Montvale, NJ: Medical Economics Co., Inc.; 2004.